HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
APLS
Apellis Pharmaceuticals Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $5.19B
Market Cap
$5.19B
Enterprise Val
$5.19B
P/E Ratio
231.65
P/B Ratio
14.01
Trailing PEG (1Y)
3.73
As Of
Apr 27, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$370.1M
Gross Margin85.13%
Profit Margin85.13%
Return on Equity8.20%
Return on Assets2.38%
Current Ratio3.14
Debt/Equity1.28
LT Debt/Equity1.01
Revenue Per Share1.58

Income Statement

Dec 31, 2025
Revenue$199.9M
Cost of Revenue$29.7M
Gross Profit$170.2M
R&D$74.2M
SG&A$147.1M
Operating Expenses$221.3M
Operating Income-$51.1M
Interest Expense$10.8M
Tax Expense$313.0K
Net Income-$59.0M
EPS (Basic)$-0.47
EPS (Diluted)$-0.45
EBIT-$47.8M
EBITDA-$47.5M
Consolidated Income-$59.0M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$467.8M
Accounts Receivable$366.2M
Inventory$177.5M
Current Assets$1.01B
LT Investments$0.00
Property, Plant & Equipment$19.9M
Intangibles$0.00
Non-Current Assets$60.4M
Total Assets$1.08B
Accounts Payable$56.8M
Current Debt$100.7M
Current Liabilities$323.6M
LT Debt$373.6M
Non-Current Liabilities$381.5M
Total Liabilities$705.1M
Total Debt$474.4M
Retained Earnings-$3.01B
Shareholder Equity$370.1M
Shares Outstanding126,525,218

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$14.2M
Investing Cash Flow-$108.0K
Financing Cash Flow$1.3M
CapEx-$108.0K
Free Cash Flow-$14.3M
Depreciation & Amort.$327.0K
Stock-Based Comp$21.2M
Acquisitions / Disposals$0.00
Investment Activity$0.00
Debt Issued/Repaid$0.00
Equity Issued/Repaid$1.3M
Dividends Paid$0.00
Net Change in Cash-$12.8M
Data cached · Meta live · Daily live · Statements live · TTL 24h